$VTIX

Virtuix holds $9 price target after fiscal 2026 results

Emerging Growth Research reiterated its Buy-Emerging rating and $9.00 price target for Virtuix (VTIX), citing strong fiscal 2026 results and growth prospects. The company reported 32% sequential revenue growth in Q4 2026, with forecasts of 15% and 290% revenue growth for fiscal 2027 and 2028, respectively. Virtuix launched Omni One for Quest, expanding its market to Meta Quest users, and continues to pursue defense opportunities.

Original reporting
Published Sep 10, 2026, 11:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 6:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Virtuix holds $9 price target after fiscal 2026 results — source image
Decision brief

The 30-second read

$VTIXBullishMed
01

Why it matters

Analyst upgrade and product launch could drive speculative buying in VTIX.

02

Market read

Microcap VR stock receives fresh analyst coverage and product launch, offering a potential short-term trade idea.

03

What to watch

Potential supply chain constraints and adoption risk.

Relevance 6/10Novelty 6/10Timing: post-launch announcement

Background

Virtuix reported strong Q4 2026 results and announced a new Omni One treadmill for Meta Quest.

Company-level read

Ticker impact

$VTIXBullishMedium confidence
Context

Analyst Emerging Growth Research set a new $9 price target and highlighted the Omni One product launch for Virtuix.

Expected impact

Short-term price pressure upward on the news.

Evidence & confidence

New analyst coverage and product launch provide fresh catalyst for a microcap.

Market effects

Highlights growth in VR hardware and defense AI applications.

May boost interest in US VR sector.

Limited to niche VR market.

Counterpoint

Price target may be overly optimistic given limited scale and competition.

Key entities

  • Virtuix Holdings Inc.

    VR hardware and defense AI platform provider.

  • Emerging Growth Research

    Research firm issuing the new price target.

Related articles

$VTIXMed

Quarterly revenue beat analyst expectations by more than 50% at Virtuix

Virtuix (VTIX) reported quarterly revenue exceeding analyst expectations by over 50%, driven by strong consumer demand for its Omni One platform. The company will present at the H.C. Wainwright conference, highlighting expansions into defense, robotics, healthcare, and enterprise markets, including partnerships with Tesla and the U.S. Marine Corps. VTIX stock declined 9.52% on the news.

$VTIXMed

Research firm sees 644% potential upside for Virtuix; orders rose 72% after Meta partnership

Emerging Growth Research reaffirmed its Buy-Emerging rating and $9.00 price target for Virtuix (VTIX), implying 644% upside. Q1 2027 revenue was $0.8M, down 26% YoY but above estimates, driven by a 72% rise in new orders post-Meta partnership. Gross margin expanded to 30%, and EPS improved sequentially to $(0.22). The firm projects 19% and 275% revenue growth for fiscal 2027 and 2028, respectively, but notes execution and financing risks.

$VTIXMed

Virtuix Holdings Inc. (VTIX): Results of Operations and Financial Condition

Virtuix Holdings Inc. (VTIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Virtuix Reports First Quarter Fiscal Year 2027 Results as Omni One Orders Increase 150% Following Meta Launch Orders Increased 72% Year-over-Year and Approximately 150% Since the Launch of Omni One for Quest as Meta Launch Drives Accelerating Consumer Demand Gross Pr

$VTIXHigh

Virtuix Q1 sales $767K, EPS ($0.22) beat estimates

Virtuix (VTIX) reported Q1 FY2027 net sales of $767K, beating estimates, with a net loss per share of ($0.22). Gross profit rose 29% to $227K, driven by higher selling prices. Operating expenses increased 86% to $4.1M. The company secured its first Omni One Enterprise sale to Tesla. Cash reserves stood at $7.4M. The earnings release and conference call were rescheduled to August 19-20, 2026, due to a new audit firm's review.

$VTIXMed

Virtuix Reports 72% Year-over-Year Order Growth, Margin Expansion, and New Defense, Enterprise, and Healthcare Wins in Fiscal Q1 2027

Virtuix reported a 72% year-over-year increase in orders and a 29% rise in gross profit for Q1 2027. Gross margin expanded to 30% from 17%. The company secured new defense, enterprise, and healthcare contracts, including deals with Tesla, NASA, and the U.S. Marine Corps. Net sales were $0.8 million, down 26% year-over-year, but orders surged.